Cyprotex offer a number of different assays to elucidate specific mechanisms of toxicity.
Phospholipidosis - lysosomal storage disorder characterized by excessive accumulation of intracellular phospholipids in tissues.
Steatosis - hepatic lipid processing disorder, leading to accumulation of triglycerides within the liver cells.
Lysosomal trapping – investigates accumulation of the drug in the lysosome.
Hemolysis - evaluates hemoglobin release in the plasma (as an indicator of red blood cell lysis).
Mitochondrial toxicity (glu/gal) – compares cytotoxicity using cells grown in glucose and galactose media to determine mitochondrial impairment.
Functional mitochondrial toxicity – uses the Seahorse XFe 96 extracellular flux analyzer to determine oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) to assess cellular bioenergetics and potential mechanisms of mitochondrial toxicity.
Reactive metabolite assessment – uses glutathione trapping studies with human liver microsomes and LC-MS/MS detection.
Cell viability - general cell viability assessment using single endpoints such as LDH (lactate dehydrogenase), neutral red or MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide).
Toxicological gene regulation – using qRT-PCR to understand toxicologically relevant changes in gene expression.
Custom toxicology – flexible service where we can investigate different cell lines, endpoints and time points to address particular customer issues.
|Mechanistic Toxicity Services|
|phospholipidosis and steatosis|
|mitochondrial toxicity (glu/gal)|
|functional mitochondrial toxicity|
|toxicological gene regulation|